Take back control of your canine otitis externa cases

Innovative Gel Formulation:

- Colourless gel squeezes out of the tube and the lipophilic formulation spreads through
- This then dissolves into the ear wax and is slowly eliminated from the ear.1 Therapeutic concentrations in the ear canals are therefore achieved and maintained²
- Harder for dogs to shake out of their ears meaning less mess, and drives enhanced compliance

Clean the ear just once



Open the tube till you hear a 'click' by twisting the soft tip.



length of the tube.



thumb and index finger of it once with a continuous your dominant hand. Make back to front motion down sure your fingers cover the the length of the tube.



Place the tube between the To empty the tube, squeeze The tube is empty when your fingertips are compressing the front end of the tube, just below the tip.

1 week later apply second dose



Get it right first time



SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT OSURNIA ear gel for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substances 1 dose (1.2 g) contains

Terbinafine: 10 mg Florfenicol: 10 mg

Betamethasone acetate: 1 mg

equivalent to Betamethasone base 0.9 mg Butvlhydroxytoluene (F321): 1 ma

3. PHARMACFUTICAL FORM

Off-white to slightly yellow translucent ge 4. CLINICAL PARTICULARS

4.2 Indications for use, specifying the target species

Treatment of acute otitis externa and acute exacerbation of recurrent otitis externa associated with Staphylococcus pseudintermedius and Malassezia pachydermatis

Do not use in case of hypersensitivity to the active substances, to other

corticosteroids or to any of the excipients

Do not use if the eardrum is perforated.

Do not use in dogs with generalised demodicosis Do not use in pregnant or breeding animals.

4.4. Special warnings for each target species

Bacterial and fungal otitis is often secondary to other conditions. Appropriate diagnosis should be used and therapy of causative conditions should be

Clean the ears before the initial treatment is applied. Ear cleaning should not be epeated until 21 days after the second administration. In clinical trials, saline only was used for ear cleaning.

Transient wetness of the inner and outer pinna can be observed. This observation is attributed to presence of product and is not of clinical concern.

4.5 Special precautions for use

Special precautions for use in animals

The safety of the product has not been established in dogs less than 2 months of

Whenever possible the use of the veterinary medicinal product should be based on dentification of infecting organisms and susceptibility testing.

Use of the veterinary medicinal product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to florfenicol and fungi resistant to terbinafine and may decrease the effectiveness of treatment with other antibiotics and antifungal agents.

In case of parasitic otitis, an appropriate acaricidal treatment should be

Before the veterinary medicinal product is applied, the external auditory canal must be examined thoroughly to ensure that the ear drum is not perforated. Prolonged and intensive use of topical corticosteroids preparation is known to trigger systemic effects, including suppression of adrenal function. (see section

Decreased cortisol levels were observed after product instillation in tolerance studies (before and after ACTH stimulation), indicating that betamethasone is absorbed and enters the systemic circulation. The finding was not correlated with

Additional corticosteroid treatments should be avoided. Use with precaution in dogs with suspected or confirmed endocrine disorder (i.e. diabetes mellitus; hypo- or hyper-thyroid disease, etc.). Special precautions to be taken by the person administering the veterinary

medicinal product to animals n case of accidental eye contact, rinse thoroughly with water. In case of accidental skin contact wash exposed skin thoroughly with water In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

No adverse reactions that could be related to the veterinary medicinal product ere observed in dogs with otitis externa under field conditions when administered

4.7 Use during pregnancy, lactation or lay

Betamethasone is known to be teratogenic in laboratory species. The safety of the veterinary medicinal product has not been established in pregnant and lactating bitches; therefore, the product should not be used during pregnancy and lactation.

4.8 Interaction with other medicinal products and other forms of

Compatibility with ear cleaners, other than saline, has not been demonstrated.

4.9 Amounts to be administered and administration route

Administer one tube per infected ear. Repeat the administration after 7 days.

Instructions for proper use: It is recommended to clean and dry the external ear canal before the first administration of the product. It is recommended not to repeat ear cleaning until 21 days after the second administration of the product. If treatment with this product is discontinued, the ear canals should be cleaned before treatment with



1. Open the tube by twisting the soft tip.

Keep out of the sight and reach of children.

3. Apply the product into the ear canal by pressing it between two fingers.
4. After application, the base of the ear may be massaged briefly and gently to facilitate even distribution of the veterinary medicinal product into the ear canal

4.10 Overdose (symptoms, emergency procedures, antidotes), if

Auricular administration of five times the recommended dose, one week apart, for 5 consecutive weeks (a total six administrations of 5 tubes per ear or 10 tubes per dog) to mixed breed dogs weighing 10 to 14 kg resulted in clinical signs of wetness of the inner and outer pinna (attributed to presence of the product). There were no clinical signs associated with unitateral vesicle formation within the epithelium of the tympanic membrane (also observed after six administrations, one week apart, of 1 tube per ear or 2 tubes per dog), unilateral mucosal ulceration in the lining of the middle ear cavity, or decrease in serum cortisol response below normal reference range in ACTH stimulation testing. The decreased adrenal and hymus weights accompanied by atrophy of the adrenal cortex and lymphoid depletion of the thymus correlated with the decreased cortisol levels, and were consistent with the pharmacologic effects of betamethasone. These findings are considered reversible. Reversibility of the epithelial tympanic membrane blistering is also likely through epithelial migration, a natural self-cleaning and self-repa chanism for the tympanic membrane and ear canal. Additionally, dogs shower slightly elevated red blood cell count, hematocrit, total protein, albumin and alanine aminotransferase. These findings were not associated with clinical signs

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Otologicals – Corticosteroids and anti-infectives in ATC-vet code: QS02CA90

5.1 Pharmacodynamic properties

ne veterinary medicinal product is a fixed combination of three active substance (corticosteroid, antifungal and antibiotic): Betamethasone acetate belongs to the diesters class of the glucocorticosteroid

with a potent intrinsic glucocorticoid activity which relieves both inflammation and pruritus leading to an improvement of clinical signs observed in otitis externa. inhibits the early synthesis of eroosterol, which is an essential component of the

membrane of yeasts and fungi including <code>Malassezia pachydermatis</code> (MIC $_{90}$ of 2 $\mu g/$ ml). Terbinafine has a different mode of action than azole antifungals, therefore there is no cross resistance with azole antifungals.

Florfenicol is a bacteriostatic antibiotic which acts by inhibiting protein synthesis Its spectrum of activity includes Gram-positive and Gram-negative bacteria including Staphylococcus pseudintermedius (MIC $_{90}$ of 8 μ g/ml). Due to the high antimicrobial concentrations achieved in the ear canal and the multifactorial nature of otitis externa. in vitro susceptibility may not be directly

5.2 Pharmacokinetic particulars

The formulation dissolves in ear wax and is slowly eliminated from the ear

Systemic absorption of all active substances was determined in multiple-dose studies after placing the veterinary medicinal product into both ear canals of nealthy mixed breed dogs. Absorption occurred primarily during the first two to our days after administration, with low plasma concentrations (1 to 42 ng/ml) of

The extent of percutaneous absorption of topical medications is determined by many factors including the integrity of the epidermal barrier. Inflammation can increase the percutaneous absorption of veterinary medicinal products.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Propylene carbonate

6.2 Incompatibilitie Not applicable.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

6.4. Special precautions for storage

Store in a refrigerator (2 °C - 8 °C).

6.5 Nature and composition of immediate packaging Single-use multi-layered aluminium and polyethylene tube with a polypropylen

Cardboard box containing 2, 12, 20 or 40 tubes (each containing 2.05 g).

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such eterinary medicinal product should be disposed of in accordance with loca

7. MARKETING AUTHORISATION HOLDER Elanco Europe Ltd.


Lilly House, Priestley Road UNITED KINGDOM

8. MARKETING AUTHORISATION NUMBER(S TU/2/14/170/0001 (2 tubes)

EU/2/14/170/0002 (12 tubes EU/2/14/170/0004 (40 tubes)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHOR Date of first authorisation: 31/07/2014

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). PROHIBITION OF SALE, SUPPLY AND/OR USE



one week apart.

done.



"Online survey conducted on 290 small animal vets in March 2016, conducted by CM Research

*Over 20% of owners have difficulty complying with once daily dosing and 80% of owners have difficulty complying with twice daily dosing

References 1. EU Pivotal Study, INT-11-011 2. Nuttal and Forster Abstract BVDSG Spring Meeting 2015 3. ANGUS J.C.: Otic cytology in health and disease. Vet. Clin. Small. Anim., 2004, 34, 411-424. **4.** Veterinary Practice News 2015.04.15 12 24 PM VPI RevealsTop10PetDisorders. **5.** Gauging interest in a new offitis externa treatment – quantitative result', Kadence International, September 2013. **6.** Oliveira L. et al. Comparative study of the microbial profile from bilateral canine offitis externa. Can Vet J 2008;49:785–788.


Osurnia ear gel for dogs contains terbinafine, florfenicol and betamethasone acetate. Legal category POM-V UK, POM IE. Information regarding the side effects, precautions, warnings and contra-indications can be found in product packaging and leaflets; further information can also be found in the Summary of Product Characteristics. For further information call Elanco Animal Health on +44 (0)1256 353131 or write to Elanco Animal Health, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL. Use medicines responsibly www.noah.co.uk/responsible. Osurnia® is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates. 2016; UKCACOSU00094




Otitis externa is a common challenge for vets and pet owners


- Ear infections are among the ten most frequent reasons for dogs to be presented to vets, affecting up to 20% of dogs^{3,4}
- Vets consider poor treatment compliance by pet owners as the most challenging aspect of managing otitis externa cases⁵


Up to 80%† of owners administer the incorrect dose of ear product to their pet.



Up to 28 applications vs 2 What would pet owners choose?








Osurnia

Osurnia

Treating Otitis Externa* just got easier!

Osurnia is **easy to use** and supports **maximum compliance** ... **done!**


- With just 2 doses, 1 week apart, you can take control of canine otitis externa treatment and help improve the clinical outcome
- Innovative adaptable gel formulation enabling optimal distribution through the ear canal and less mess



- Same dose for any dog, regardless of their size and weight
- Pre-measured, single-use tubes for the right dose every time

A first line treatment that you can prescribe with confidence for your Otitis Externa* cases ... done!

• Osurnia is a unique sustained release gel:




Antifungal Contains terbinafine Effective against Malassezia spp.

Anti-inflammatory

Contains betamethasone acetate

Helps to relieve discomfort

• Field trials prove that just 2 doses of Osurnia treats otitis externa effectively



The most common pathogens associated with otitis are Staphylococcus pseudintermedius and Malassezia pachydermatis⁶

Comfortable dogs and peace of mind for owners brought through innovation ... done!

- Flexible soft tip gentle for a dog's ears that makes otitis externa treatment a comfortable experience for the dog
- You take control of treatment and remove product administration from the owners' hands making everybody's life easier

For more comfortable dogs and happier owners, choose enhanced compliance with Osurnia